Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …

Abstract Interleukin 31 (IL-31) is a neurocytokine that stimulates sensory neurons involved in
pruritus. It contributes to skin barrier inflammation, dysfunction, and remodeling. As the …

Background Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis
(AD) pathogenesis. Objective We sought to evaluate a new dosing strategy of nemolizumab …

Pruritus represents one of the most common symptoms in dermatology and general
medicine. Chronic pruritus severely impairs the quality of life of affected patients. During the …

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease. It has a
complex pathophysiology, with a combination of immune dysregulation and intrinsic barrier …

Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31)
receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai …

Background Interleukin-31 may play a role in the pathobiologic mechanism of atopic
dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab …

Background: Atopic dermatitis, a chronic inflammatory disease, has a lifetime prevalence of
10–20%. Atopic dermatitis reduces quality of life, primarily due to pruritus. Interleukin-31 and …

Background Nemolizumab is a humanized anti‐IL‐31 receptor blocker in phase 3 for atopic
dermatitis (AD). Objective Analyse onset of action of nemolizumab 30 mg and compare …

Introduction Nemolizumab, a new monoclonal antibody that targets the receptor alpha of the
neuroimmune cytokine interleukin-31 (IL-31), has shown efficacy in atopic dermatitis (AD) in …